Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Cost of Revenue (2022 - 2026)

Indivior Pharmaceuticals has reported Cost of Revenue over the past 5 years, most recently at $40.0 million for Q1 2026.

  • For Q1 2026, Cost of Revenue fell 9.09% year-over-year to $40.0 million; the TTM value through Mar 2026 reached $242.0 million, up 1.26%, while the annual FY2025 figure was $246.0 million, 6.49% up from the prior year.
  • Cost of Revenue for Q1 2026 was $40.0 million at Indivior Pharmaceuticals, down from $67.0 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $83.0 million in Q3 2025 and troughed at $38.0 million in Q2 2022.
  • A 5-year average of $51.7 million and a median of $48.0 million in 2023 define the central range for Cost of Revenue.
  • Biggest five-year swings in Cost of Revenue: soared 58.0% in 2024 and later plummeted 34.18% in 2025.
  • Year by year, Cost of Revenue stood at $43.0 million in 2022, then rose by 20.93% to $52.0 million in 2023, then decreased by 3.85% to $50.0 million in 2024, then soared by 34.0% to $67.0 million in 2025, then crashed by 40.3% to $40.0 million in 2026.
  • Business Quant data shows Cost of Revenue for INDV at $40.0 million in Q1 2026, $67.0 million in Q4 2025, and $83.0 million in Q3 2025.